Risk of prostate cancer and its correlation with different biochemical parameters in non diabetic men
Keywords:
Prostate specific antigen, Diabetes, non-diabetics, Blood glucose, High density lipoproteinAbstract
Background: It has been hypothesized that men with long term diabetes have a lower risk of prostate cancer then non-diabetic men. Whether diabetes influences level of biomarkers such as prostate specific antigen (PSA), which is involved in the detection of prostate cancer is, unknown. In view of the aforementioned controversial literature, it was decided to evaluate this relation-ship in non-diabetic men. We evaluated the correlation between fasting glucose, prostate specific antigen and different biochemical lipid profile parameters with serum uric acid and serum creatinine in non-diabetic male between age group 40-61 years.
Methods: Association between fasting serum glucose , different lipid parameters, serum uric acid, serum creatinine and prostate specific antigen in 83 non-diabetic males aged 40 to 61years were studied retrospectively. Glucose and lipid parameters and serum creatinine, serum uric acid were measured on fully automated analyser using standard reagent kits. Serum prostate specific antigen was measured by TOSOH-AIA-360, immunoassay method.
Results: Correlations between different biochemical parameters were determined. Prostate specific antigen were negatively correlated with HDL (r= -0.22, p= 0.03) in age group 40-61 years. At the same fasting blood sugar were correlated positively(r= 0.34, p= 0.02 ) with prostate specific antigen in age group 51-60 years , but not in age group 40-50 years.
Conclusion: We concluded that serum HDL (high density lipoprotein) was negatively associated and FBS (fasting blood sugar) was positively associated with risk of prostate cancer. We also suggest that in men of this age group a low HDL level should not be ignored while assessing prostate cancer risk especially if accompanied with an elevated FBS level even in the upper normal range.
Metrics
References
Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009; 16: 1103–1123.
Li Q, Kuriyama S, Kakizaki M, et al. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes Control. 2010; 21:1025–1032.
Tseng CH, Chong CK, Tai TY. Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006. Diabetologia. 2009; 52:240–246.
Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care.2010;33:1674–1685.
Leitzmann MF, Ahn J, Albanes D, et al. Prostate, Lung, Colorectal, and Ovarian Trial Project Team. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Cancer Causes Control. 2008;19:1267–1276.
Prostate cancer Incidence and Mortality Worldwide in 2008, Globocan 2008, cancer fact sheet.
Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH, Chen J. Changing trends of prostate cancer in Asia. Aging Male.2004; 7: 120–132.
Tseng CH, Chong CK, Tseng CP, Chan TT. Age-related risk of mortality from bladder cancer in diabetic patients: a 12-year follow-up of a national cohort in Taiwan. Ann Med.2009; 41:371–379.
Muller H, Raum E, Rothenbacher D, Stegmaier C, Brenner H. Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiol Biomarkers Prev.2009; 18: 1350–1356.
Hammarsten J, Högstedt B. Clinical, hemodynamic, anthropometric, metabolic and insulin profile of men with high‐stage and high‐grade clinical prostate cancer. Blood Press 2004;13(1):47-55.
Bach L, RechlerM. Insulin-like growth factors and diabetes. Diabet Metab Rev. 1992;8:229-57.
Kasper JS, Giovannucci E. A meta analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev2006;15: 2056-62.
Chodick G, Heymann AD, Rosenmann L, et al. Diabetes and risk of incident Cancer: a large population-based cohort study in Israel. Cancer Causes Control. 2010;21:879-87.
Chin-hsiaotseng, MD, PHD. Diabetes and Risk of Prostate Cancer A study usingthe National Health Insurance. Diabetes Care.2011;34: 616–621.
American urological association. Prostate –specific antigen (PSA) best practice policy. Oncology .2000; 14: 267-286.
Foulkes WD .Inherited susceptibility to common cancers. N Engl J Med .2008;359, 2143-53.
Hoffman RM .Clinical practice. Screening for prostate cancer. N Engl J Med.2011;365, 2013 -9.
Mori M, Masumori N, Fukuta F, et al .Weight gain and family history of prostate or breast cancers as risk factors for prostate cancer: results of a case-control study in Japan. Asian Pac J Cancer Prev. 2011;12: 743-7.
Lilja H, Christensson A, Dahlen U et al. Prostate- specific antigen in serum occurs predominantly in complex with alpha 1 antichymotrypsin. Clinical chem.1991;37:1618-1625.
Stenman UH, Leinonnen J, Alfithan H, et al. A complex between prostate –specific antigen and alpha 1- anti chymotrypsin is the major form of prostate cancer. Asay of the complex improves clinical sensitivity of cancer. Cancer Res.1991; 51:222-226.
Diamandis EP. prostate –specific antigen: a cancer fighter and a valuable messenger? Clin chem.2000; 46: 896-900.
Diamandis EP. Prostate- specific antigen: its usefulness in clinical medicine. Trends endocrinol meteb. 1998; 9: 310-316.
Oesterling JE, Jacobsen SJ, Chute CG, etal. Serum prostate- specific antigen in a community – based population of healthy men: establishment of age specific reference ranges. JAMA 1993;270: 860- 864.
Salazar-Martinez E, Lazcano-Ponce EC, Lira-Lira GG, et al. Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer among Mexican women. Cancer Causes Control 2000;11:707-11.
Chen CQ, Fang LK, Cai SR, et al. Effects of diabetes mellitus on prognosis of the patients with colorectal cancer undergoing resection: a cohort study with 945 patients. Chin Med J (Engl). 2010; 123, 3084-8.
Onitilo AA, Engel JM, Glurich I, et al. Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control. 2012;23, 967-81.
Fukui M, Tanaka M, Kadono M, Imai S, Hasegawa G, Yoshikawa T et al. Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes Care 2008; 31: 930–931.
Werny DM, Saraiya M, Gregg EW. Prostate-specific antigen values in diabetic and nondiabetic US men 2001–2002. Am J Epidemiol. 2006; 164: 978–983.
Long XJ, Lin S, Sun YN, Zheng ZF. Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(8):4097-100.
Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Annu Rev Med.1988; 39:465–490.
Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem.1992; 38: 1933–1953.
Carl A. Burtis, Edward Ashwood, David E Bruns. Teitz fundamentals of Clinical chemistry, Elsevier, a division of Reed Elsevier India private Limited: 5th edition: 2001;398-399.
Sree Kumari S, Vasudevan. Text book of biochemistry for medical students Jaypee Brothers Medical Publishers(P) LTD; 3rd edition:2001;339.
Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, Landis P, Platz EA. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91:2562–2568.
Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate.2010;70:79-89.
Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta. 2006; 370:89-93.
